Microtubule-targeted drugs are essential chemotherapeutic agents for various types of cancer. We have previously reported the synthesis of 3-vinyl-β-lactams (2-azetidinones) with potent antiproliferative activity against breast cancer MCF-7 cells . As a continuation of our research work on tubulin polymerization inhibitors, we now present the synthesis and biochemical evaluation of a series of novel 3-isopropenyl-β-lactams (2-azetidinones) that are structurally related to the colchicine binding site tubulin inhibitor and vascular targeting agent, Combretastatin A-4. The 3-isopropenyl-β-lactams in this series contain 3,4,5-trimethoxyphenyl ring A, (required for CA-4), together with selected ring B substituents . These compounds showed potent activity against breast cancer in MCF-7 and MDA-MB-231 cells and are minimally toxic to non-tumorigenic HEK-293T cells. Moreover, the compounds significantly arrested cell division during the G2/M phase and induced apoptosis in the MCF-7 cell line. Immunofluorescence studies in MCF-7 cells showed that the 3-isopropenyl-β-lactam caused mitotic catastrophe by targeting tubulin and inhibited tubulin polymerization. In conclusion, the 3-isopropenyl-2-azetidinones could be promising lead compounds for the development of anti-breast cancer drugs that target tubulin in future clinical trials.
Previous Article in event Previous Article in session
Next Article in event
Chromatographic retention factor obtained on immobilized keratin stationary phase - what molecular properties does it encode?Next Article in session
Synthesis and Biological Evaluation of Novel 3-Isopropenyl-β-lactams: Heterocyclic Bridged Analogues of Combretastatin A-4 as Novel Antimitotic Agents in Breast Cancer
Published: 01 November 2022 by MDPI in 8th International Electronic Conference on Medicinal Chemistry session Small molecules as drug candidates
Keywords: Combretastatin A-4; MCF-7 cells; β-lactams (2-azetidinones), Antimitotic Agents